Genitofemoral neuralgia: adding to the burden of chronic vulvar pain

Hans Verstraelen1  
Eline De Zutter1  
Martine De Muynck2

1Department of Obstetrics and Gynaecology, Vulvovaginal Disease Clinic, Ghent University Hospital, Ghent, Belgium; 2Department of Physical Medicine and Rehabilitation, Ghent University Hospital, Ghent, Belgium

Abstract: The vulva is a particularly common locus of chronic pain with neuropathic characteristics that occurs in women of any age, though most women with neuropathic type chronic vulvar pain will remain undiagnosed even following multiple physician visits. Here, we report on an exemplary case of a middle-aged woman who was referred to the Vulvovaginal Disease Clinic with debilitating vulvar burning and itching over the right labium majus that had been persisting for 2 years and was considered intractable. Careful history taking and clinical examination, followed by electrophysiological assessment through somatosensory evoked potentials was consistent with genitofemoral neuralgia, for which no obvious cause could be identified. Adequate pain relief was obtained with a serotonin–noradrenaline reuptake inhibitor and topical gabapentin cream. We briefly discuss the epidemiology, diagnosis, and treatment of genitofemoral neuralgia and provide a series of clues to guide clinicians in obtaining a presumptive diagnosis of specific neuropathic pain syndromes that may underlie chronic vulvar pain. We further aim to draw attention to the tremendous burden of chronic, unrecognized vulvar pain.

Keywords: vulvar pain, genitofemoral nerve, neuropathic pain, vulvodynia, vulvar disease

Introduction
Neuropathic pain is an umbrella term that has recently been redefined by the International Association for the Study of Pain as pain caused by a lesion or disease of the somatosensory system,1 thereby encompassing a number of diverse conditions and body sites. Although largely underappreciated, the vulva is a particularly common locus of chronic pain with neuropathic characteristics in women of any age. In the largest community-based study conducted thus far, chronic “unexplained” vulvar pain, defined as burning or sharp knife-like pain or pain on contact, that lasted for at least 3 months or longer was reported by nearly 7% of women aged 18–64 years in a US urban area.2 In spite of this high prevalence, it was also revealed in the latter study that no proper diagnosis was provided to a majority of women suffering from chronic vulvar pain even following multiple physician visits,2 a finding that has been corroborated by several recent US population-based studies.3,4 Here, we report on a case of a middle-aged woman with chronic vulvar neuropathic pain that, although unique from a clinical perspective, exemplifies the burden of unrecognized chronic vulvar pain from a public health view, as discussed further.

Case presentation
A 45-year-old woman was referred to the Vulvovaginal Disease Clinic with debilitating vulvar burning and itching over the right labium majus, also causing severely
disturbed sleep. Vulvar pain had been persisting for 2 years and was considered intractable. Careful history taking revealed that she had two vaginal deliveries and was known to suffer from Crohn’s disease involving the right hemicolectomy, terminal ileum, and rectum, for which she was treated with azathioprine orally and rectally applied mesalazine. The patient also had a laparoscopic fallopian tube ligation. Finally, she had a history of atopy, and reported occasional seasonal allergic rhinitis symptoms.

The patient was initially followed at a regional hospital. A blind biopsy was taken from the right labial skin in a dermatology practice; it showed no epidermal or dermal anomalies. Several topical treatments were initiated empirically, including vaginal antibiotic and fungistatic agents and various corticoid ointments, without providing relief. During a surgical consult, a nodule was detected in the right labium majus and was the presumed cause of the chronic pain. It was removed under general anesthesia, and had histological features indicative of a ruptured hair follicle. As no diagnosis was obtained, the patient was also asked to discontinue all medications, including those for treatment of Crohn’s disease. The patient was eventually referred to our hospital, which is a tertiary referral center.

Careful examination of the vulva and vagina revealed neither visible anomalies nor any other findings indicative of vulvar inflammatory, infectious, or neoplastic mucocutaneous disease. During the clinical exam, the patient was asked to point out the pain area, showing the right labiocutaneous fold, the anterior surface of the right labium majus, and right medial upper thigh, though burning sensation of the right labium majus showed a prolonged latency (32.2 versus 9.1 ms corresponding to 10% prolongation) and considered intracutaneous nerves (white) with accompanying innervation zones (dashed lines), and the most common location of vulvodynia, i.e., the vulvar vestibule (yellow). Cutaneous nerve distribution in this anatomical region is however highly variable with numerous anatomical variants having been described, complicating clinical diagnosis of neuropathic pain origin in this anatomical region.

Careful history taking and a daily dose of 7.5 mg per day at intervals of 50 mg was reached. While reporting mild side effects of vivid dreaming and increased transpiration, Venlafaxine was slowly titrated, starting with a dose of 37.5 mg and adding up in increments of 37.5 mg per day at intervals of 7 days, until a daily dose of 150 mg was reached. While reporting mild side effects of vivid dreaming and increased transpiration,
the patient experienced rapid improvement of vulvar pain, which allowed her to resume normal sleep at night, after 2 years of sleep deprivation. She gradually tapered off use of the lidocaine patch and reported that she no longer experienced vulvar discomfort during activities of daily life. In view of the side effects under venlafaxine, the treatment regimen was changed to duloxetine 60 mg a day, resulting in disappearance of the side effects, while maintaining optimal pain relief of the vulva. Discomfort over the right thigh, primarily described as itching rather than burning, did persist however, for which we initiated a compounded topical gabapentin cream in a 6% concentration formulated in a nonionic cream, resulting in significant relief of discomfort over the right thigh. At some point in time during follow-up, the patient reported a slight but hindering exacerbation of vulvar pain under duloxetine. Careful history taking revealed that the pain reoccurred following a bicycle day trip, and the patient was therefore instructed on vulvar care with emphasis on limiting vulvar mechanical strain as a known aggravating factor. One year after initial assessment, the patient remains pain free under continued treatment with duloxetine orally 60 mg a day and 6% gabapentin cream applied twice daily. For this kind of approach or publication, Ghent University Hospital Institutional Review Board approval was not deemed necessary by our institution. Written informed consent from the patient was obtained.

Discussion

According to the International Society for the Study of Vulvovaginal Disease, vulvar pain can broadly be classified as pain related to a specific disorder, either as pain occurring in the absence of relevant visible findings or a specific clinically identifiable, neurologic disorder.5 Vulvar pain attributable to a specific disorder basically encompasses pain resulting from infectious disease (eg, herpes genitalis), inflammatory mucocutaneous disease (eg, lichen planus), neoplastic disease (eg, squamous cell carcinoma), and neurological disease (eg, postherpetic neuralgia).1 In the event that no such underlying disease to vulvar pain can be identified, the term vulvodynia has been adopted,4 though etymologically referring to vulvar pain as such. Vulvodynia involves in the vast majority of patients mechanical allodynia and hyperalgesia of the vaginal vestibular area, thought to relate at least in part to marked regional C-fiber hyperinnervation and possibly neuroinflammation.6 While the nosology of vulvodynia has been a long-standing matter of debate,5,7,8 clearly, the signs and symptoms in vulvodynia show considerable overlap with neuropathic pain,9 as assessed by available screening tools.10

Women presenting with chronic nociceptive vulvar pain typically elicit visible epithelial alterations (eg, lichen planus, vulvar intraepithelial neoplasia, and genitourinary syndrome of menopause) prompting clinical diagnosis, though histopathological confirmation following biopsy might be sought, and hence most of these, often older patients, will eventually be managed accordingly. Paradoxically, women presenting with the more common neuropathic type of chronic vulvar pain, resulting from vulvodynia or specific neuropathic pain syndromes, usually do not show visible anomalies, and either do not seek medical attention or remain undiagnosed even following multiple physician visits.3,4,11 A recent population-based study revealed, for instance, that merely 3% of women meeting vulvodynia criteria were actually diagnosed with vulvodynia.3

Illustrating this point is the significant diagnostic delay observed in the case we presented, as well as the strong physician tendency to attribute the pain reported by the patient to visible or demonstrable tissue alterations, prompting biopsy and surgery, as well as the number of treatments directed toward infectious and inflammatory conditions, even though no such diagnosis was obtained.

While chronic “unexplained” vulvar pain is a debilitating condition affecting a vast number of women of all ages,2 this has been mostly attributed to vulvodynia epidemiology, and hence it has not been established how often chronic vulvar pain is associated with specific neuropathic pain syndromes related to neuralgia of the genitofemoral, ilioinguinal, and pudendal nerves (Figure 1), though not a rarity at a vulvar disease clinic in our experience.

Genitofemoral neuralgia was first described by Magee12 as genitofemoral causalgia, and subsequently redefined by Lyon,13 where the current nomenclature was introduced.14 Genitofemoral neuralgia in women is almost exclusively known as an iatrogenic pain disorder, complicating common lower abdominal and pelvic surgical procedures such as inguinal herniorrhaphy, cesarean section, hysterectomy, and lymph node biopsy, as recently and comprehensively reviewed by Cesmebasi et al.14 In the original case series by Magee,12 there is also mention of an 11-year-old girl who developed genitofemoral neuralgia after falling while bicycling, presumably involving direct trauma to the groin by the handle bar.13 Murovic et al.,15 in their series of ten patients, also reported on four patients who developed genitofemoral neuralgia after blunt abdominal trauma. We identified only one case report on spontaneous-onset genitofemoral neuralgia,
not related to surgery or blunt trauma, involving a 20-year-old woman, in which nerve compression was suspected to result from tight-fitting clothing. Interestingly, also with regard to the case presented by us, bicycle riding has also been reported as a possible factor evoking genitofemoral neuralgia. Tight-fitting clothing and bicycling are often reported as aggravating or evoking factors in patients with vulvodynia or neuropathic pain attending our vulvar disease clinic, pointing at vulvar mechanical strain through pressure and friction as an important aggravating and possibly initiating factor to chronic vulvar disease, though this is poorly addressed in the medical literature. We cannot explain how the patient presented developed genitofemoral neuralgia, though possibly resulting from a tubal ligation procedure. A relationship with Crohn’s disease could not be established.

The mainstay to the diagnosis of genitofemoral neuralgia has been the use of selective nerve blocks, as originally proposed by Lichtenstein et al. Historically, this technique involved an essentially blind block near the pubic tubercle, distal to the presumed site of injury following most types of surgery, and with a considerable potential for injury to the surrounding structures at the injection site. Due to the retroperitoneal location dorsal to the psoas muscle, the genitofemoral nerve has been notoriously difficult to target more proximally. Recently, several medical imaging-guided transperitoneal techniques have been described by use of computed tomography and ultrasound, magnetic resonance neurography-guided nerve blocks are likely to serve as another excellent diagnostic tool. In case of clinical suspicion of genitofemoral, ilioinguinal, or pudendal neuralgia, we initially obtain electrophysiological assessment through SSEP, an approach that has not been reported in this context in the literature before. We identified one case report in which ilioinguinal nerve entrapment was suspected through electromyography in a 35-year-old man with acute scrotal pain. Clearly, the sensitivity of electrophysiological approaches needs to be validated in sufficiently large patient series; however, it has proven a useful noninvasive first-line diagnostic assessment in our experience.

A myriad of therapeutic approaches for genitofemoral neuralgia have been described as comprehensively reviewed by Cesmebasi et al, including ultrasound-guided nerve block injections, various ablative techniques for neurolysis, and genitofemoral neurectomy, recently described through an endoscopically retroperitoneal approach. It may be acknowledged that neurolysis or neurectomy of the genitofemoral nerve may be accompanied by hypohesthesia over the labium majus, possibly impairing sexual function. Noninvasive, pharmacotherapeutic approaches may provide proper pain relief in a substantial proportion of patients. A recent systematic review by the Special Interest Group on Neuropathic Pain of the International Association for the Study of Pain found sufficient evidence to strongly recommend tricyclic antidepressants, serotonin–noradrenaline reuptake inhibitors, pregabalin, and gabapentin as first-line treatments in neuropathic pain. In the patient presented here, as with many other patients presenting with chronic vulvar pain, satisfactory pain relief was obtained with serotonin–noradrenaline reuptake inhibitors and topical gabapentin.

In summary, it is widely observed that although many women of all ages suffer from chronic neuropathic type vulvar pain, most of these will remain undiagnosed even following multiple physician visits. A majority of these patients presumably have vulvodynia, while an unknown number of women suffer from a specific neuropathic vulvar pain condition. Although physicians such as dermatologists, urologists, and gynecologists are largely unfamiliar with these conditions, several clues to the diagnosis of genitofemoral, ilioinguinal, or pudendal neuralgia may be particularly useful in the first- or second-line assessment when confronted with the chronic vulvar pain patient (Table 1): 1) careful history taking reveals continuous vulvar pain, often reported as a burning sensation (though possibly also involving itch, tingling, or sharp pain); 2) pain or discomfort is typically unilateral; 3) vulvar pain or discomfort may be most pronounced while sitting, and least prominent when lying; 4) clinical and

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Clues to vulvar neuralgia diagnosis in the patient with chronic vulvar pain</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>History taking</strong></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>Continuous vulvar pain, possibly disturbing sleep at night</td>
</tr>
<tr>
<td>2.</td>
<td>Pain character often described as burning, though possibly also involving itch, tingling, or sharp pain</td>
</tr>
<tr>
<td>3.</td>
<td>Pain interferes with activities of daily life</td>
</tr>
<tr>
<td>4.</td>
<td>Dyspareunia possibly present, but not obligate</td>
</tr>
<tr>
<td>5.</td>
<td>Pain often increases upon pressure of friction imposed to the vulvar area (pants, sitting, bicycle riding, etc)</td>
</tr>
<tr>
<td>6.</td>
<td>Postural gradient in pain intensity may be present: pain most pronounced while sitting, less when standing, and least while lying down</td>
</tr>
<tr>
<td><strong>Clinical examination</strong></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>Inspection of the vulva does not reveal any relevant anomalies</td>
</tr>
<tr>
<td>2.</td>
<td>Even if anomalies are observed, these do not necessarily correlate with subjective symptoms</td>
</tr>
<tr>
<td>3.</td>
<td>Pain is typically unilateral</td>
</tr>
<tr>
<td>4.</td>
<td>Pain conferred to a well-described vulvar area</td>
</tr>
<tr>
<td>5.</td>
<td>Pain possibly exacerbated by maximal hip flexion</td>
</tr>
<tr>
<td>6.</td>
<td>Tactile sense testing over the vulvar area referred often reveals aberrant sensory responses (in comparison to the contralateral side), including allodynia, hyperesthesia, and hypoesthesia</td>
</tr>
</tbody>
</table>
microbiological analysis does not reveal anomalies, and even if anomalies are observed, these do not necessarily correlate with subjective symptoms, especially since symptoms are unilateral; 5) vulvar pain may be provoked by maximal hip flexion; and 6) tactile sense anomalies may be demonstrated by the use of ordinary disposables available in most physician offices. Finally, first-line treatment may be initiated according to current evidence with tricyclic antidepressants, serotonin–noradrenaline reuptake inhibitors, pregabalin, and gabapentin, whereby it is crucial to inform the patient on the treatment rationale, expected treatment success, and possible side effects.

Acknowledgments
We would like to thank radiologist Pieter De Visschere for carefully reviewing the MRI images. We are also greatly indebted to Jan De Groote for his valuable contribution in designing the illustration.

Disclosure
The authors report no conflicts of interest in this work.

References